Short facts  
API BI1029539
Technology Oral
Indication Microvascular disease
Development phase Preclinical
Expected filing with FDA -
In-house or partnership Partnership with Gesynta Pharma AB

The concept

The lead candidate drug in the OX-MPI program, BI1029539, has been identified as a highly selective anti-inflammatory compound targeting microsomal prostaglandin E synthase (mPGES-1).

OX-MPI is fully managed by Gesynta Pharma AB.